HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data

Homologous recombination deficiency (HRD) is a critical feature guiding drug and treatment selection, mainly for ovarian and breast cancers. As it cannot be directly observed, HRD status is estimated on a small set of genomic instability features from sequencing data. The existing methods often perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuwen, Xu, Ying, Zhang, Yinbin, Wang, Shenjie, Zhang, Xuanping, Yi, Xin, Zhang, Shuqun, Wang, Jiayin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554509/
https://www.ncbi.nlm.nih.gov/pubmed/36246633
http://dx.doi.org/10.3389/fgene.2022.990244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554509/
https://www.ncbi.nlm.nih.gov/pubmed/36246633
http://dx.doi.org/10.3389/fgene.2022.990244

Ejemplares similares